On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advancing DehydraTECH Drug Delivery Platform, Innovative Products

  • Lexaria Bioscience is focusing on its pioneering DehydraTECH drug delivery technology
  • The company boasts a portfolio of unique products
  • Lexaria continues to conduct research regarding DehydraTECH technology for oral nicotine

Based in Kelowna, British Columbia, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Lexaria is the only global company with patents issued for the oral delivery of all cannabinoids. The company has developed and out-licenses its innovative and cost-effective DehydraTECH drug delivery platform. This technology changes the way that edible cannabinoids enter the body. DehydraTECH delivery technology offers a viable and often healthier substitute to other delivery processes for bioactive substances (http://ibn.fm/yih3f).

Lexaria Biosciences’ proprietary technology improves the taste, speed and delivery of bioactive compounds, including nicotine and cannabinoids. DehydraTECH is proven effective in multiple worldwide studies in significantly assisting the quantity of absorption of a range of lipophilic (fat-soluble) bioactive molecules. DehydraTECH also eliminates the strong tastes and odors of lipophilic compounds. Notably, this technology does so without the need for added sugar or sweeteners (http://ibn.fm/BPOdn).

Furthermore, the DehydraTECH drug delivery platform increases bio-absorption by up to 10 times and lessens the time of onset, with effects being felt within 15 to 20 minutes, as compared to 60 to 120 minutes without the platform. In addition, the technology is patent protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids. Patents are also granted for THC (tetrahydrocannabinol), other psychoactive compounds and NSAIDs (nonsteroidal, anti-inflammatory drugs), as well as nicotine and other molecules.

Lexaria Bioscience has partnered with one of the world’s largest tobacco companies to fund the research and development of the DehydraTECH technology for oral nicotine. Through wholly owned subsidiary Lexaria Nicotine LLC, Lexaria is working to propel innovation in oral, reduced-risk nicotine consumer products utilizing DehydraTECH (http://ibn.fm/1JjdR).

Lexaria’s goal is to perform an extensive series of clinical investigations of oral types of nicotine delivery, funded by its partner, using DehydraTECH technology. The DehydraTECH platform has been shown to deliver nicotine to the brain quicker than traditional delivery systems. The technology could potentially apply to the treatment of nervous system diseases, including Alzheimer’s disease. Moreover, DehydraTECH avoids the dangers associated with smoking.

Lexaria also offers a suite of diverse products (http://ibn.fm/Mnu7n). These products include protein energy bars featuring fiber and protein; ViPova exotic teas, delivering cannabidiol in numerous flavors; and coffee. The company also sells TurboCBD capsules. These are high-absorption, full-spectrum hemp oil capsules. The capsules are designed to boost focus and memory while at the same time lessening fatigue and stress. TurboCBD capsules also contain ginseng and gingko.

Lexaria Bioscience is developing a patent family with supporting intellectual property (IP) in the pharmaceutical sector. Lexaria Pharmaceutical Corp. is the company’s wholly owned subsidiary. Lexaria Pharmaceutical has acquired exclusive international rights to Lexaria’s patent portfolio regarding pharmaceutical applications (http://ibn.fm/QNwSp).

Additionally, Lexaria Hemp Co. holds exclusive international rights to the Lexaria Bioscience patent portfolio regarding hemp-based applications. The Lexaria group also includes Lexaria CanPharm Corp., a Canadian entity. Lexaria CanPharm owns exclusive international rights to Lexaria’s IP applicable to psychotropic bioactive molecules, which act upon human CB1 and CB2 receptors in permitted areas.

Lexaria Bioscience is innovating on multiple fronts. The company’s business model offers the potential for considerable ROI, as it involves developing and out-licensing its DehydraTECH platform to third-party partners and distributors for enhanced revenue. Lexaria continues to move forward with its DehydraTECH drug delivery platform and the sale of company-developed and joint venture products.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

Last Tweets

Follow us: @Buy_Stocks_Now

From Our Blog

Pressure BioSciences Inc.’s (PBIO) PCT Platform Featured in 15 Independent Scientific Presentations

June 24, 2019

The presentations were held during the annual American Society of Mass Spectrometry conference – an event attended by more than 10,000 scientists Research focused on a wide range of applications ranging from cancer research to biomarker discovery The number of PCT-related presentations during the 2019 conference exceeded prior Pressure BioSciences records for a scientific meeting, […]

Rotate your device 90° to view site.